Sanford Burnham Prebys Medical Discovery Institute

Sanford-Burnham Medical Research Institute

Southern Research Institute

La Jolla Institute for Allergy and Immunology

Jiwen Zou

Robert J Ardecky

Anthony B Pinkerton

Santhi Reddy Ganji

Nicholas D P Cosford

Nunzio Bottini

Michael P Hedrick

Eduard A Sergienko

Stephanie M Stanford

Thomas D Y Chung

Marintha L Heil

Marcos Gonzalez-Lopez

John Howard Hutchinson

Nick Cosford

Leo Bleicher

Robert John Ardecky

Nicholas DP Cosford

Santhi R Ganji

Thomas Chung

Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof

Herein are provided, inter, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A). 

Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof

Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A). 

Provided is a method for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus, as well as novel compounds that are useful in the method.

Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections

Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.

Spirocyclic EBI2 modulators

Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.

EBI2 modulators

Provided is a process for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus. The process includes administering to the subject a therapeutically effective amount of at least one compound represented by the formula: (Formula (I)) 

The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R, R, R, R, R, R, R, and Rare as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.

Growing community of inventors

La Jolla, CA, United States of America

Jiwen Zou